AI-assisted international press reviewPress review

Ris-Rez: 67% Reduction in Osteosarcoma Progression Risk in China

Results from the ARTEMIS-011 trial show that Ris-Rez significantly improves progression-free survival in patients with relapsed osteosarcoma, offering new hope in a field where treatment options are limited. GSK continues to develop this promising treatment across various solid tumors.

Source: Gsk, published under the title "Ris-Rez reduced risk of disease progression or death by 67% ..." - 27 October 2026

Abbott Launches Genomic Sequencing Test to Detect Residual Disease in Oncology

Abbott's new Oncodetect® test, utilizing whole genome sequencing and MAESTRO technology, enables unprecedented sensitivity in detecting traces of cancer. By targeting up to 5,000 patient-specific variants, this test offers promising prospects for managing solid tumors, assisting physicians in assessing recurrence risk and tailoring treatments. Preliminary results from clinical studies indicate a significant improvement in residual disease detection, underscoring the importance of innovation in oncology.

Source: Abbott, published under the title "Abbott Launches Whole-Genome Sequencing Oncodetect® Molecula..." - 26 October 2026

Bayer Secures Approval for Asundexian, First FXIa Inhibitor in China

The approval of asundexian by the Chinese medical products administration marks a significant advancement in the treatment of non-cardioembolic ischemic strokes, providing a new therapeutic option for at-risk patients. Based on promising results from the OCEANIC-STROKE study, this medication could transform stroke management in China, where this condition is the leading cause of death and disability.

Source: Bayer, published under the title "Asundexian first Factor XIa inhibitor approved in China for ..." - 26 October 2026

Pimicotinib: Two Years of Promising Results for TGCT Treatment

Results from a two-year study on pimicotinib reveal significant and lasting improvements in symptoms for patients with tenosynovial giant cell tumor (TGCT), with a stable tumor response rate and a good tolerance profile. These advancements highlight the drug's potential to enhance patients' quality of life, as it is already approved in China and Canada, and awaiting approval in the United States.

Source: Merck, published under the title "Two-Year Data of Pimicotinib Demonstrated Durable Tumor Cont..." - 26 October 2026

Tagrisso and Orpathys: Major Advances in Lung Cancer Treatment

Results from the SAFFRON trial reveal that the combination of Tagrisso and Orpathys significantly reduces the risk of disease progression and death in patients with non-small cell lung cancer with EGFR mutation, establishing a new standard of care.

Source: Astrazeneca, published under the title "Tagrisso plus Orpathys reduced the risk of disease progressi..." - 26 October 2026

Sonesitatug Vedotin: A Major Breakthrough in Advanced Gastric Cancer Treatment

Promising results from the CLARITY-Gastric01 trial show that sonesitatug vedotin significantly reduces the risk of death in patients with advanced gastric cancers positive for CLDN18.2, paving the way for a new treatment standard. With a 42% reduction in death risk in the second line and 53% in the third line, this targeted therapy could transform the therapeutic options available for these patients.

Source: Astrazeneca, published under the title "Sonesitatug vedotin reduced the risk of death by 42% in 2nd-..." - 26 October 2026

Amivantamab Shows Promising Results for Head and Neck Cancer

Johnson & Johnson has revealed encouraging results from a clinical study on amivantamab, a bispecific antibody, showing an overall response rate of 77% in patients with head and neck cancer. These results support the ongoing development of this innovative treatment, which targets EGFR and MET receptors, often involved in tumor progression. The observed adverse effects were manageable, reinforcing hope for improved therapeutic options for these patients.

Source: J&j - 26 October 2026

Promising Results for JNJ-6143: An Innovative Prostate Cancer Treatment

Johnson & Johnson announces encouraging results for JNJ-6143, an experimental drug that specifically targets prostate cancer cells. In a phase 1 study, 75% of patients showed a positive response after multiple prior treatments, with significant reductions in PSA levels. This treatment, based on the RIPTAC platform, could offer a new option for patients suffering from advanced prostate cancer, a condition that is often difficult to treat.

Source: J&j - 25 October 2026

Imfinzi and Enfortumab Vedotin: Major Advances Against Bladder Cancer

Results from the VOLGA trial demonstrate that perioperative treatment with Imfinzi and enfortumab vedotin significantly reduces the risk of recurrence and death in patients with muscle-invasive bladder cancer, offering a promising new therapeutic perspective.

Source: Astrazeneca, published under the title "Perioperative Imfinzi plus neoadjuvant enfortumab vedotin re..." - 25 October 2026

Imfinzi and Imdelltra: A Major Breakthrough Against Lung Cancer

Results from the DeLLphi-305 trial reveal a significant reduction in the risk of death and an improvement in median survival for patients with advanced small cell lung cancer, thereby establishing new treatment standards.

Source: Astrazeneca, published under the title "Imfinzi plus Imdelltra reduced the risk of death by 58% in 1..." - 25 October 2026

Promising Results of Jemperli in Treating Advanced Rectal Cancer

Data reveals that 76% of patients with advanced MSI-H/dMMR rectal cancer achieved a complete response after treatment with Jemperli, with no reported recurrences after more than two years of follow-up. These results support the recent approval of the drug in the United States and will be presented during an oral session at ESMO.

Source: Gsk, published under the title "Jemperli (dostarlimab) data show 76% of patients with MSI-H/..." - 25 October 2026

Apalutamide: A Promising Advancement Against Prostate Cancer

Results from a clinical study indicate that the combination of apalutamide and androgen deprivation therapy significantly reduces the risk of recurrence and metastasis in high-risk prostate cancer patients, offering a potential alternative to surgery alone. These findings, presented at the ESMO 2026 congress, underscore the importance of an early approach in treating this disease.

Source: J&j - 25 October 2026

Darolutamide Reduces Metastasis Risk by 58% in Prostate Cancer Patients

An interim analysis of the DASL-HiCaP trial reveals that adding darolutamide to standard therapy significantly improves metastasis-free survival in high-risk recurrence patients. With a metastasis-free survival rate of 95% compared to 88% for placebo, these promising results will be presented at the ESMO 2026 Congress, highlighting the importance of early intervention in prostate cancer treatment.

Source: Bayer, published under the title "Darolutamide plus ADT and radiation therapy reduces risk of ..." - 24 October 2026

Novartis Reports Promising Results for Remibrutinib in Multiple Sclerosis

During a presentation at MSToronto2026, Novartis revealed that remibrutinib, a selective oral Bruton’s tyrosine kinase inhibitor, demonstrated superior efficacy in controlling relapses and significantly delaying disease progression in patients with relapsing multiple sclerosis, without any hepatic safety signals. These results could provide a new therapeutic option for patients.

Source: Novartis, published under the title "Novartis remibrutinib delivered comprehensive disease contro..." - 24 October 2026

Abbott Enhances Sensitivity of Oncodetect® Test for Colorectal Cancer

At the ESMO 2026 congress, Abbott presented data from the Beta-CORRECT study, demonstrating that its Oncodetect® test, based on whole genome sequencing, offers increased sensitivity for detecting colorectal cancer recurrences, thereby enhancing the prognostic value of molecular residual disease (MRD) testing. These advancements underscore the importance of early detection and patient monitoring post-treatment.

Source: Abbott, published under the title "Abbott Presents New ESMO Data Showing 30-Percent Absolute Im..." - 24 October 2026

GSK Reveals Promising Results for Mo-Rez in Ovarian Cancer

GSK has announced encouraging results for its Mo-Rez treatment, demonstrating an objective response rate of 62% and a median response duration of 12.2 months in a Phase Ib trial. These results come in the context of platinum-resistant ovarian cancer, with a median progression-free survival of 11.1 months. Five Phase III studies are currently underway to evaluate the efficacy of Mo-Rez in various gynecological cancers.

Source: Gsk, published under the title "GSK presents positive data for Mo-Rez in platinum-resistant ..." - 24 October 2026

Kisqali® Shows Significant Overall Survival Improvement in HR+/HER2- Breast Cancer

The six-year analysis results from the NATALEE trial indicate that Kisqali® (ribociclib) combined with endocrine therapy reduces the risk of death by nearly 20% in patients with high-risk HR+/HER2- breast cancer. These findings reinforce Kisqali's role as a standard treatment, with benefits continuing to increase over time and no new safety issues reported. These results will be presented at the ESMO 2026 congress.

Source: Novartis, published under the title "Kisqali® shows clinically meaningful overall survival in bro..." - 23 October 2026

Johnson & Johnson Unveils Promising Advances in Oncology with JNJ-6143

At the ESMO 2026 congress, Johnson & Johnson will present significant clinical results on JNJ-6143, an innovative treatment for prostate cancer, as well as data on other solid tumors. These results underscore the company's commitment to transforming cancer treatment through innovative biological approaches and addressing unmet medical needs.

Source: J&j - 23 October 2026

Finerenone Shows Promising Results for Kidney Protection Without Diabetes

New analyses from the FIND-CKD study indicate that finerenone significantly reduces proteinuria and slows the decline of kidney function in patients with chronic kidney disease without diabetes, particularly those suffering from focal segmental glomerulosclerosis and IgA nephropathy. These findings highlight the importance of finerenone as a therapeutic option in this clinical context.

Source: Bayer, published under the title "Finerenone showed consistent effects in reduction of UPCR, U..." - 23 October 2026

Johnson & Johnson Unveils Advances in Electrophysiology at APHRS 2026

At the Asia Pacific Heart Rhythm Society 2026, Johnson & Johnson presented significant results from the VARIPURE and Omny-IRE studies, demonstrating the efficacy and safety of its new pulsed field ablation technologies for treating atrial fibrillation, with high success rates and notable improvements in patients' quality of life.

Source: J&j - 22 October 2026